Notizie su Zealand Pharma

Ultime notizie

Titoli nella lingua originale della fonte.

• 
  Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) (si apre in una nuova scheda)

  GlobeNewswire · 5 ott 2026

• 
  Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts (si apre in una nuova scheda)

  1 ott 2026

• Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial (si apre in una nuova scheda)

  MT Newswires · 1 ott 2026

• 
  Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes (si apre in una nuova scheda)

  GlobeNewswire · 1 ott 2026

• 
  Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 (si apre in una nuova scheda)

  GlobeNewswire · 30 set 2026

• 
  Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology (si apre in una nuova scheda)

  GlobeNewswire · 29 set 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) (si apre in una nuova scheda)

  GlobeNewswire · 28 set 2026

• 
  Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity (si apre in una nuova scheda)

  GlobeNewswire · 22 set 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) (si apre in una nuova scheda)

  GlobeNewswire · 21 set 2026

• 
  Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome (si apre in una nuova scheda)

  GlobeNewswire · 18 set 2026

• 
  Zealand Pharma (CPSE:ZEAL) Grants Exclusive Type 1 Diabetes Peptide License (si apre in una nuova scheda)

  Simply Wall St. · 18 set 2026

• Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes (si apre in una nuova scheda)

  15 set 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) (si apre in una nuova scheda)

  GlobeNewswire · 14 set 2026

• 
  Zealand Pharma increases its share capital as a result of the exercise of employee warrants (si apre in una nuova scheda)

  GlobeNewswire · 10 set 2026

• Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference (si apre in una nuova scheda)

  9 set 2026

• Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) (si apre in una nuova scheda)

  7 set 2026

• Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (si apre in una nuova scheda)

  2 set 2026

• Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough (si apre in una nuova scheda)

  1 set 2026

• Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (si apre in una nuova scheda)

  31 ago 2026

• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (si apre in una nuova scheda)

  28 ago 2026